Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures
Abstract Multiple myeloma (MM) is a malignant disorder characterized by clonal proliferation of plasma cells. Renal impairment is a common complication. Contrast-induced nephropathy (CIN) is a form of acute renal failure that can occur in the setting of IV contrast administration. It is more commonly seen in patients with pre-existing renal impairment. Patients with MM commonly require contrast enhanced procedures. The literature regarding the safety of IV contrast in this cohort is lacking. A retrospective review was carried out in a university hospital to identify the incidence of CIN in patients with MM and to look for associated risk factors. 94 patients and 165 procedures were included in the analysis. 10% of procedures resulted in CIN. 59% (10/17) of creatinines had normalized within one month of the procedure. The only factor found to be significant for the development of CIN was the timing of the procedure (<18mths verses >18mths post diagnosis of MM; p = 0.045). CIN appears to occur at an increased rate in patients with MM. However this may be an over-estimation given the common occurrence of renal impairment in this cohort and the close temporal relationship which often exists between systemic illness and contrast-enhanced procedures..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Pathology & oncology research - 24(2017), 4 vom: 13. Sept., Seite 915-919 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Crowley, Maeve P. [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
Anmerkungen: |
© Arányi Lajos Foundation 2017 |
---|
doi: |
10.1007/s12253-017-0300-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR025079271 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR025079271 | ||
003 | DE-627 | ||
005 | 20230519100726.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12253-017-0300-9 |2 doi | |
035 | |a (DE-627)SPR025079271 | ||
035 | |a (SPR)s12253-017-0300-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Crowley, Maeve P. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Arányi Lajos Foundation 2017 | ||
520 | |a Abstract Multiple myeloma (MM) is a malignant disorder characterized by clonal proliferation of plasma cells. Renal impairment is a common complication. Contrast-induced nephropathy (CIN) is a form of acute renal failure that can occur in the setting of IV contrast administration. It is more commonly seen in patients with pre-existing renal impairment. Patients with MM commonly require contrast enhanced procedures. The literature regarding the safety of IV contrast in this cohort is lacking. A retrospective review was carried out in a university hospital to identify the incidence of CIN in patients with MM and to look for associated risk factors. 94 patients and 165 procedures were included in the analysis. 10% of procedures resulted in CIN. 59% (10/17) of creatinines had normalized within one month of the procedure. The only factor found to be significant for the development of CIN was the timing of the procedure (<18mths verses >18mths post diagnosis of MM; p = 0.045). CIN appears to occur at an increased rate in patients with MM. However this may be an over-estimation given the common occurrence of renal impairment in this cohort and the close temporal relationship which often exists between systemic illness and contrast-enhanced procedures. | ||
650 | 4 | |a Multiple myeloma |7 (dpeaa)DE-He213 | |
650 | 4 | |a Contrast induced nephropathy |7 (dpeaa)DE-He213 | |
650 | 4 | |a Complications |7 (dpeaa)DE-He213 | |
700 | 1 | |a Prabhakaran, Vinitha N. |4 aut | |
700 | 1 | |a Gilligan, Oonagh M. |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pathology & oncology research |d Heidelberg : Springer, 1995 |g 24(2017), 4 vom: 13. Sept., Seite 915-919 |w (DE-627)SPR025050133 |w (DE-600)2002501-4 |x 1532-2807 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2017 |g number:4 |g day:13 |g month:09 |g pages:915-919 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12253-017-0300-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 24 |j 2017 |e 4 |b 13 |c 09 |h 915-919 |